Human Molecular Genetics, 2000, Vol. 9, No. 17 2507-2515
© 2000 Oxford University Press
Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for Duchenne muscular dystrophy
1Department of Pediatrics, Division of Medical Genetics and 2Department of Human Genetics, Duke University Medical Center, Durham, NC 27710, USA and 3Department of Human Genetics, University of Michigan, Ann Arbor, MI, USA
Duchenne muscular dystrophy (DMD) is an X-linked recessive disease caused by the lack of expression of the dystrophin protein in muscle tissues. We genetically engineered a mouse model (mdx) of DMD that allowed for the high level and inducible transcription of a dystrophin mini-gene. This was achieved via the tetracycline-responsive transactivator (tTA) system. Multiple analyses confirmed that dystrophin expression in the mice was: (i) tTA dependent; (ii) correctly localized to the sarcolemmal membranes; (iii) capable of preventing the onset of dystrophy; and (iv) effectively blocked by the oral administration of tetracyclines. The model allowed us to somatically extinguish or induce dystrophin gene transcription. Somatic induction of dystrophin transcription prevented the onset of muscular dystrophy in some muscle groups. The levels of phenotypic rescue were influenced, however, by the age of the animals at the time of dystrophin induction. We also found that despite somatic termination of dystrophin gene transcription, the dystrophin protein was found to be associated with the sarcolemmal membrane for at least 26 weeks. Persistent detection of dystrophin was also accompanied by a prolonged protection of the muscle cells from the onset of dystrophy. The findings demonstrated that somatic transfer of the dystrophin gene not only may allow for the prevention of muscular dystrophy in multiple muscle groups, but also may be accompanied by persistent efficacy, secondary to the long-term functional stability of the dystrophin protein in vivo. This model should be useful in future studies concerning the potential of genetic therapy for DMD, as well as other muscle disorders.
+ To whom correspondence should be addressed. Tel: +1 919 681 6356; Fax: +1 919 684 2362; Email: amalf001@mc.duke.edu
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. Yin, H. M. Moulton, Y. Seow, C. Boyd, J. Boutilier, P. Iverson, and M. J.A. Wood Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function Hum. Mol. Genet., December 15, 2008; 17(24): 3909 - 3918. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Ghahramani Seno, I. R. Graham, T. Athanasopoulos, C. Trollet, M. Pohlschmidt, M. R. Crompton, and G. Dickson RNAi-mediated knockdown of dystrophin expression in adult mice does not lead to overt muscular dystrophy pathology Hum. Mol. Genet., September 1, 2008; 17(17): 2622 - 2632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. G. Nguyen, G. Yu, M. Makitalo, D. Yang, H.-X. Xie, M. R. Jones, and K. Ravid Conditional overexpression of transgenes in megakaryocytes and platelets in vivo Blood, September 1, 2005; 106(5): 1559 - 1564. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Morrison, D. B. Palmer, S. Cobbold, T. Partridge, and G. Bou-Gharios Effects of T-Lymphocyte Depletion on Muscle Fibrosis in the mdx Mouse Am. J. Pathol., June 1, 2005; 166(6): 1701 - 1710. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Squire, J.M. Raymackers, C. Vandebrouck, A. Potter, J. Tinsley, R. Fisher, J.M. Gillis, and K.E. Davies Prevention of pathology in mdx mice by expression of utrophin: analysis using an inducible transgenic expression system Hum. Mol. Genet., December 15, 2002; 11(26): 3333 - 3344. [Abstract] [Full Text] [PDF]
|
|